Suchergebnisse - "KINASE inhibitors"

Efficacy of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma: a comparison with transarterial chemoembolization combined with TKIs.

Autoren: Fan L Wang L

Quelle: Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] 2025 Dec; Vol. 66 (12), pp. 1311-1318. Date of Electronic Publication: 2025 Sep 02.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Sage Country of Publication: England NLM ID: 8706123 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0455 (Electronic) Linking ISSN: 02841851 NLM ISO Abbreviation: Acta Radiol Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/drug therapy , Chemoembolization, Therapeutic*/methods , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Infusions, Intra-Arterial ; Hepatic Artery ; Aged ; Treatment Outcome ; Combined Modality Therapy ; Adult ; Antineoplastic Agents/administration & dosage ; Tyrosine Kinase Inhibitors

Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia.

Autoren: Kota V Wei D Yang D et al.

Quelle: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 743-752. Date of Electronic Publication: 2025 May 21.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

MeSH-Schlagworte: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/economics , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/economics , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/economics, Humans ; Retrospective Studies ; Male ; Middle Aged ; Female ; Adult ; Aged ; Insurance Claim Review ; United States ; Cost of Illness ; Health Expenditures/statistics & numerical data ; Young Adult ; Dasatinib/therapeutic use ; Dasatinib/economics ; Tyrosine Kinase Inhibitors

Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma.

Autoren: Riaza Montes M Suárez B Solano-Iturri JD et al.

Quelle: International journal of molecular sciences [Int J Mol Sci] 2025 Nov 17; Vol. 26 (22). Date of Electronic Publication: 2025 Nov 17.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/metabolism , Carcinoma, Renal Cell*/mortality , Gelatinases*/metabolism , Gelatinases*/genetics , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/metabolism , Kidney Neoplasms*/pathology , Serine Endopeptidases*/metabolism , Serine Endopeptidases*/genetics , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/pharmacology , Membrane Proteins*/metabolism , Membrane Proteins*/genetics , Neoplasm Recurrence, Local*/metabolism , Neoplasm Recurrence, Local*/pathology , Neoplasm Recurrence, Local*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Aged ; Endopeptidases ; Prognosis ; Adult ; Biomarkers, Tumor/metabolism ; Cancer-Associated Fibroblasts/metabolism ; Cancer-Associated Fibroblasts/pathology ; Aged, 80 and over ; Disease-Free Survival ; Tyrosine Kinase Inhibitors

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies.

Autoren: Huntjens DW Béquignon OJM Krens SD et al.

Quelle: British journal of clinical pharmacology [Br J Clin Pharmacol] 2025 Nov; Vol. 91 (11), pp. 3130-3140. Date of Electronic Publication: 2025 Jul 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Protein Kinase Inhibitors*/pharmacokinetics , Protein Kinase Inhibitors*/chemistry , Artificial Intelligence* , Models, Biological* , Malabsorption Syndromes*/metabolism, Humans ; Biological Availability ; Proton Pump Inhibitors/pharmacology ; Intestinal Absorption/drug effects ; Hydrogen-Ion Concentration ; Solubility ; Neural Networks, Computer ; Drug Monitoring/methods ; Tyrosine Kinase Inhibitors

Overall Survival with Amivantamab-Lazertinib in EGFR -Mutated Advanced NSCLC.

Autoren: Yang JC Lu S Hayashi H et al.

Körperschaften: Yang JC Lu S Hayashi H et al.

Quelle: The New England journal of medicine [N Engl J Med] 2025 Oct 30; Vol. 393 (17), pp. 1681-1693. Date of Electronic Publication: 2025 Sep 07.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

Info zur Zeitschrift: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

MeSH-Schlagworte: Acrylamides*/administration & dosage , Acrylamides*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/mortality , Lung Neoplasms*/genetics , Tyrosine Kinase Inhibitors*/administration & dosage , Tyrosine Kinase Inhibitors*/adverse effects, Aged ; Female ; Humans ; Male ; Middle Aged ; Aniline Compounds/administration & dosage ; Aniline Compounds/adverse effects ; ErbB Receptors/genetics ; ErbB Receptors/antagonists & inhibitors ; Kaplan-Meier Estimate ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Antibodies, Bispecific/administration & dosage ; Antibodies, Bispecific/adverse effects ; Indoles/administration & dosage ; Indoles/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Survival Rate ; Infusions, Intravenous ; Progression-Free Survival ; Morpholines ; Pyrazoles

Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.

Autoren: Mavridis E Hadjipavlou-Litina D

Quelle: International journal of molecular sciences [Int J Mol Sci] 2025 Oct 20; Vol. 26 (20). Date of Electronic Publication: 2025 Oct 20.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH-Schlagworte: Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/pharmacokinetics , Protein Kinase Inhibitors*/pharmacology , Cheminformatics*/methods , Protein-Tyrosine Kinases*/antagonists & inhibitors , Protein-Tyrosine Kinases*/metabolism , Protein-Tyrosine Kinases*/chemistry , Drug Discovery*/methods, Humans ; Molecular Docking Simulation ; Computer Simulation ; Tyrosine Kinase Inhibitors

Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.

Autoren: Shao W Yang K Lu D et al.

Quelle: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2025 Oct 16; Vol. 110 (11), pp. e3857-e3865.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE

MeSH-Schlagworte: Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/administration & dosage , Endocrine System Diseases*/chemically induced , Endocrine System Diseases*/epidemiology , Neoplasms*/drug therapy, Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Adult ; Incidence ; Drug Therapy, Combination/adverse effects ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Young Adult ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Follow-Up Studies ; Aged, 80 and over ; Tyrosine Kinase Inhibitors

[Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation].

Autoren: Yuan MY Li ZR Zhang XS et al.

Quelle: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2025 Oct 14; Vol. 46 (10), pp. 929-936.

Publikationsart: English Abstract; Journal Article

Info zur Zeitschrift: Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727 (Print) Linking ISSN: 02532727 NLM ISO Abbreviation: Zhonghua Xue Ye Xue Za Zhi Subsets: MEDLINE

MeSH-Schlagworte: Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/psychology , Substance Withdrawal Syndrome*/epidemiology , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Leukemia, Myeloid, Chronic-Phase*/psychology, Humans ; Adult ; Middle Aged ; Female ; Retrospective Studies ; Male ; Incidence ; Logistic Models ; Tyrosine Kinase Inhibitors

Long-Term Safety of Tofacitinib for Treatment of Moderate-to-Severe Ulcerative Colitis: Three Years of Korean National Data.

Autoren: Song EM Seo GH Jung SH

Quelle: Journal of Korean medical science [J Korean Med Sci] 2025 Oct 13; Vol. 40 (39), pp. e259. Date of Electronic Publication: 2025 Oct 13.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Korean Academy of Medical Science Country of Publication: Korea (South) NLM ID: 8703518 Publication Model: Electronic Cited Medium: Internet ISSN: 1598-6357 (Electronic) Linking ISSN: 10118934 NLM ISO Abbreviation: J Korean Med Sci Subsets: MEDLINE

MeSH-Schlagworte: Colitis, Ulcerative*/drug therapy , Colitis, Ulcerative*/pathology , Pyrimidines*/therapeutic use , Pyrimidines*/adverse effects , Piperidines*/therapeutic use , Piperidines*/adverse effects , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects, Humans ; Female ; Male ; Middle Aged ; Republic of Korea/epidemiology ; Adult ; Aged ; Databases, Factual ; Herpes Zoster/epidemiology ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Tumor Necrosis Factor Inhibitors/adverse effects ; Risk Factors ; Young Adult ; Incidence ; Janus Kinase Inhibitors/therapeutic use ; Janus Kinase Inhibitors/adverse effects ; Thromboembolism/epidemiology ; Thromboembolism/etiology ; Severity of Illness Index

Sensitive analysis of tyrosine kinase inhibitors in plasma using polypropylene fabric-solid phase extraction combined with liquid chromatography-tandem mass spectrometry.

Autoren: Wang D Li M Dai T et al.

Quelle: Journal of chromatography. A [J Chromatogr A] 2025 Oct 11; Vol. 1760, pp. 466315. Date of Electronic Publication: 2025 Aug 23.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9318488 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3778 (Electronic) Linking ISSN: 00219673 NLM ISO Abbreviation: J Chromatogr A Subsets: MEDLINE

MeSH-Schlagworte: Tandem Mass Spectrometry*/methods , Solid Phase Extraction*/methods , Solid Phase Extraction*/instrumentation , Protein Kinase Inhibitors*/blood , Protein Kinase Inhibitors*/isolation & purification , Protein Kinase Inhibitors*/chemistry , Polypropylenes*/chemistry, Reproducibility of Results ; Chromatography, Liquid/methods ; Limit of Detection ; Humans ; Linear Models ; Tyrosine Kinase Inhibitors

Histopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.

Autoren: Nykaza I Platero-Portillo T Berman E et al.

Quelle: The American Journal of dermatopathology [Am J Dermatopathol] 2025 Dec 01; Vol. 47 (12), pp. 920-929. Date of Electronic Publication: 2025 Sep 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7911005 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-0311 (Electronic) Linking ISSN: 01931091 NLM ISO Abbreviation: Am J Dermatopathol Subsets: MEDLINE

MeSH-Schlagworte: Protein Kinase Inhibitors*/adverse effects , Drug Eruptions*/pathology , Drug Eruptions*/etiology , Antineoplastic Agents*/adverse effects, Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Imidazoles/adverse effects ; Tyrosine Kinase Inhibitors

Cerebral aspergillosis in a patient treated with acalabrutinib, a second generation Bruton's tyrosine kinase inhibitor.

Autoren: Rezig S Talarmin JP Le Gal S et al.

Quelle: Journal de mycologie medicale [J Mycol Med] 2025 Dec; Vol. 35 (4), pp. 101586. Date of Electronic Publication: 2025 Oct 20.

Publikationsart: Case Reports; Journal Article

Info zur Zeitschrift: Publisher: Masson Country of Publication: France NLM ID: 9425651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1773-0449 (Electronic) Linking ISSN: 11565233 NLM ISO Abbreviation: J Mycol Med Subsets: MEDLINE

MeSH-Schlagworte: Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors , Pyrazines*/adverse effects , Pyrazines*/therapeutic use , Benzamides*/adverse effects , Benzamides*/therapeutic use , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/therapeutic use , Neuroaspergillosis*/chemically induced , Neuroaspergillosis*/diagnosis , Neuroaspergillosis*/microbiology, Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Male ; Fatal Outcome ; Aged ; Middle Aged ; Tyrosine Kinase Inhibitors

Brutons tyrosine kinase inhibitor Zanubrutinib modulates Fc gamma receptors to inhibit platelet destruction for alleviation of refractory immune thrombocytopenia.

Autoren: Yang XX Yao GL Yang YJ et al.

Quelle: Hematology (Amsterdam, Netherlands) [Hematology] 2025 Dec; Vol. 30 (1), pp. 2545078. Date of Electronic Publication: 2025 Oct 06.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

MeSH-Schlagworte: Pyrazoles*/pharmacology , Pyrazoles*/therapeutic use , Purpura, Thrombocytopenic, Idiopathic*/drug therapy , Purpura, Thrombocytopenic, Idiopathic*/metabolism , Purpura, Thrombocytopenic, Idiopathic*/blood , Receptors, IgG*/metabolism , Blood Platelets*/metabolism , Blood Platelets*/drug effects , Blood Platelets*/pathology , Piperidines*/pharmacology , Piperidines*/therapeutic use , Pyrimidines*/pharmacology , Pyrimidines*/therapeutic use , Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Tyrosine Kinase Inhibitors

Receptor tyrosine kinase inhibitor tivozanib regulates cell state plasticity and restores MITF dependency in BRAF wild-type melanoma.

Autoren: Ma YN Ma XH Hao ML et al.

Quelle: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2025 Dec; Vol. 46 (12), pp. 3327-3342. Date of Electronic Publication: 2025 Jun 23.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE

MeSH-Schlagworte: Melanoma*/drug therapy , Melanoma*/pathology , Melanoma*/metabolism , Melanoma*/genetics , Microphthalmia-Associated Transcription Factor*/metabolism , Microphthalmia-Associated Transcription Factor*/antagonists & inhibitors , Microphthalmia-Associated Transcription Factor*/genetics , Proto-Oncogene Proteins B-raf*/genetics , Proto-Oncogene Proteins B-raf*/metabolism , Proto-Oncogene Proteins B-raf*/antagonists & inhibitors , Quinolines*/pharmacology , Quinolines*/therapeutic use , Phenylurea Compounds*/pharmacology , Phenylurea Compounds*/therapeutic use , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/therapeutic use , Cell Plasticity*/drug effects , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Humans ; Cell Line, Tumor ; Animals ; Cell Proliferation/drug effects ; Drug Synergism ; Mice, Nude ; Tyrosine Kinase Inhibitors

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?

Autoren: Caserta S Martino EA Vigna E et al.

Quelle: European journal of haematology [Eur J Haematol] 2025 Dec; Vol. 115 (6), pp. 599-609. Date of Electronic Publication: 2025 Sep 13.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

MeSH-Schlagworte: Lymphoma, Mantle-Cell*/drug therapy , Lymphoma, Mantle-Cell*/metabolism , Lymphoma, Mantle-Cell*/mortality , Lymphoma, Mantle-Cell*/etiology , Lymphoma, Mantle-Cell*/diagnosis , Agammaglobulinaemia Tyrosine Kinase*/antagonists & inhibitors , Agammaglobulinaemia Tyrosine Kinase*/metabolism , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/adverse effects, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Molecular Targeted Therapy ; Disease Management ; Drug Resistance, Neoplasm ; Treatment Outcome ; Tyrosine Kinase Inhibitors

Variable response of germline activating PDGFRB variants to receptor tyrosine kinase inhibitors: implications for treatment.

Autoren: Cristea I Mehrasa R Gladkauskas T et al.

Quelle: European journal of human genetics : EJHG [Eur J Hum Genet] 2025 Dec; Vol. 33 (12), pp. 1668-1676. Date of Electronic Publication: 2025 Oct 15.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9302235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5438 (Electronic) Linking ISSN: 10184813 NLM ISO Abbreviation: Eur J Hum Genet Subsets: MEDLINE

MeSH-Schlagworte: Receptor, Platelet-Derived Growth Factor beta*/genetics , Receptor, Platelet-Derived Growth Factor beta*/antagonists & inhibitors , Receptor, Platelet-Derived Growth Factor beta*/metabolism , Germ-Line Mutation* , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/pharmacology, Humans ; Tyrosine Kinase Inhibitors

Cheminformatics-based analysis identified Novel compounds from Nelumbo nucifera as potential inhibitors targeting PI3k/Akt/mTOR Pathway of HR+/HER2- subtype for Breast Cancer.

Autoren: Ahmed SF Barua P Amin MA et al.

Quelle: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2025 Nov 28; Vol. 791, pp. 152953. Date of Electronic Publication: 2025 Nov 10.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Phosphoinositide-3 Kinase Inhibitors* , Antineoplastic Agents, Phytogenic*/chemistry , Antineoplastic Agents, Phytogenic*/pharmacology, Humans ; TOR Serine-Threonine Kinases/metabolism ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Female ; Molecular Docking Simulation ; Signal Transduction/drug effects ; Receptor, ErbB-2/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Molecular Dynamics Simulation ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Phytochemicals/chemistry ; Phytochemicals/pharmacology ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology

Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.

Autoren: Bao M Zhang XS Li ZR et al.

Quelle: Cancer [Cancer] 2025 Nov 15; Vol. 131 (22), pp. e70166.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

MeSH-Schlagworte: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/mortality , Azacitidine*/administration & dosage , Azacitidine*/adverse effects , Protein Kinase Inhibitors*/administration & dosage , Protein Kinase Inhibitors*/adverse effects , Protein Kinase Inhibitors*/therapeutic use , Blast Crisis*/drug therapy , Blast Crisis*/genetics , Blast Crisis*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Adult ; Prospective Studies ; Aged ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Pyridazines/administration & dosage ; Pyridazines/adverse effects ; Biomarkers, Tumor/genetics ; Treatment Outcome ; Mutation ; Tyrosine Kinase Inhibitors

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.

Autoren: Pecci F Li H Di Federico A et al.

Quelle: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Nov 14; Vol. 31 (22), pp. 4802-4813.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/mortality , Proto-Oncogene Proteins c-met*/genetics , Proto-Oncogene Proteins c-met*/antagonists & inhibitors , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/administration & dosage , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Mutation* , Exons*/genetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/therapeutic use ; Adult ; Aged, 80 and over ; Neoplasm Metastasis ; Tyrosine Kinase Inhibitors

Mechanistic optimization of inavolisib combined with CDK4/6 inhibitors in the treatment of PIK3CA-mutated breast tumors.

Autoren: Zhu R Zhang H Zhang F

Quelle: Frontiers in immunology [Front Immunol] 2025 Nov 06; Vol. 16, pp. 1693927. Date of Electronic Publication: 2025 Nov 06 (Print Publication: 2025).

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Class I Phosphatidylinositol 3-Kinases*/genetics , Class I Phosphatidylinositol 3-Kinases*/antagonists & inhibitors , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Mutation* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/pharmacology, Humans ; Female ; Animals ; Aminopyridines/therapeutic use ; Purines/therapeutic use ; Pyridines/therapeutic use ; Phosphoinositide-3 Kinase Inhibitors ; Imidazoles ; Oxazoles